Navigation Links
MedWaves, Incorporated Announces Receipt of Taiwan Food and Drug Administration (TFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices
Date:9/21/2011

SAN DIEGO, Sept. 21, 2011 /PRNewswire/ -- MedWaves' AveCure™ microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over 1,000 patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The Company plans to bring its technology to treat lesions in other locations in the body. The Company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options.

Taiwan, with over 23 million in population, is one of 15 highly developed Asian countries in the region, an important market for MedWaves. As with other developed countries in the region, its cancer incidence rate is on the rise, and cancer remains the leading cause of death in Taiwan as its life expectancy continues to rise according to Taiwan Today, June 2011. The five most common types of cancer in 2008 were colon, liver, lung, breast and oral cancer according to Taiwan Central News Agency, April 2011. MedWaves is pleased to announce the receipt of TFDA certification to import and sell its products to help those in need. MedWaves will work in close coordination with its Taiwanese distributor-partners to schedule and conduct clinical evaluations for the sale of its AveCure™ system in key hospitals in Taiwan. Earlier this year, Hong Kong University published its successful treatment of tumors in the liver using the MedWaves AveCure™ microwave ablation system. The Hong Kong University has adopted the MedWaves™ AveCure system as a cancer treatment tool.

About AveCure™ Microwave Coagulation-Ablation System and Devices:

MedWaves AveCure™ Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented, fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumors, safely and easily, with confidence. This single-patient-use device provides MedWaves with a continuous growth of revenue stream.

MedWaves AveCure™ Microwave Coagulation-Ablation System has also received USFDA approval for sales in the United States*, CE Mark for sales in the European Union, KFDA certification for import and sales in Korea, and SFDA certification for import and sales in China. Other received approval and certification announcements to follow.

About MedWaves, Incorporated

MedWaves, Inc., a United States company based in San Diego, California, develops innovative and proprietary microwave ablation technology for the minimally invasive coagulation-ablation products for soft tissue lesions, such as tumors. The Company's management team has extensive experience in the medical device marketplace. The Company's proprietary technology allows for the development of minimally invasive microwave antenna devices in a wide range of sizes, shapes and flexibility to meet the clinicians' requirements in the treatment of lesions in bone, kidney, liver, lung, pancreas and other locations in the body. MedWaves maintains California FDB and ISO 13485 Certifications to manufacture and distribute microwave coagulation-ablation system.

Contact Information:

Theodore Ormsby (email: tedormsby@avecure.com)  
Mobile: (858) 342-3331

George Leung, PhD (email: gleung@avecure.com)  
Mobile: (858) 705-5056

16760 W Bernardo Drive, San Diego, CA 92127        
Tel: (858) 946-0015              
Website: http://www.medwaves.com  

*The system is not intended for use in cardiac procedures.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE MedWaves, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Incorporated to Speak at UBS Global Life Sciences Conference
2. Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
3. Accuray Incorporated to Host Investor Meeting at ASTRO 2011
4. Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement
5. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
6. Accuray Incorporateds CEO to Speak at Jefferies 2011 Global Healthcare Conference
7. Accuray Incorporated Announces HSR Clearance in Acquisition of TomoTherapy
8. Accuray Incorporated to Report Financial Results for Third Quarter of Fiscal 2011
9. Accuray Incorporated to Speak at 10th Annual Needham Healthcare Conference
10. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
11. Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proactas PR509 Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):